A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.

Source:http://linkedlifedata.com/resource/pubmed/id/18339140

Download in:

View as

Triples

General Info

PMID
18339140